The Effect of Oxytocin on Face Perception

Early Phase 1

Suspended

• Conditions: Healthy; Congenital Prosopagnosia
• Interventions: Drug: Oxytocin; Drug: Placebo

• Registration Number: NCT02091817
• Lead Sponsor: Soroka University Medical Center

Brief Summary

The purpose of this study is to determine whether oxytocin affect face perception

Detailed Description

Not available

Study Timeline

• Study Start: 2013-11
• Study First Submitted: 2014-01-26
• Study First Submitted QC: 2014-03-17
• Study First Posted: 2014-03-19
• Status Verified: 2015-07
• Last Update Submitted: 2015-07-01
• Last Update Posted: 2015-07-02
• Primary Completion: 2016-12
• Study Completion: 2017-12

Recruitment & Eligibility

• Status: SUSPENDED
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• normal or corrected to normal vision

Exclusion Criteria

• minors
• pregnancy (according to a pregnancy test taken by subjects prior to participation)
• a history of asthma or nasal polyps
• cardiac disorders
• hyponatremia
• acute or chronic renal insufficiency
• liver cirrhosis
• neurological disease
• other chronic disease
• dementia, or lack of judgment

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Control group	Oxytocin	Control group will be administered oxytocin and placebo, in a double-blind randomized order.
Control group	Placebo	Control group will be administered oxytocin and placebo, in a double-blind randomized order.
congenital prosopagnosia	Placebo	Congenital prosopagnosics will be administered oxytocin and placebo in a double-blind randomized order.
congenital prosopagnosia	Oxytocin	Congenital prosopagnosics will be administered oxytocin and placebo in a double-blind randomized order.

Primary Outcome Measures

Name	Time	Method
Memory performance	Day 2 (24 hours after encoding)	At the day participants will administer the substance, they will view a set of faces, of which they will be tested about 24 hours later. The measures that will be tested are %accuracy and %dwell time of eye movements towards each region in the faces the participants saw.

Secondary Outcome Measures

Name	Time	Method
Mood measurement	Day 1 (after oxytocin/placebo uptake)	Participants will fill a PANAS mood questionnaire in order to monitor the effects of mood and fatigue of oxytocin/placebo. We will use ANOVA on the total score of the test in order to verify that differences in performance are not due to change in mood or fatigue after substance uptake.

Trial Locations

Locations (1)

Soroka medical center; 🇮🇱 Beer Sheva, Israel